Sagimet Biosciences Inc. (NASDAQ: SGMT) appointed Andreas Grauer, MD, as chief medical officer, effective April 20, 2026, according to a company press release. The clinical-stage biopharmaceutical company develops therapeutics targeting metabolic and fibrotic pathways.

Grauer replaces Eduardo Bruno Martins, MD, DPhil, who retired from the position and will continue as an external scientific advisor. Martins served as chief medical officer for five years.

Grauer brings more than two decades of biopharmaceutical experience across clinical development, medical affairs, and regulatory strategy. He most recently served as chief medical officer at Omeros Corporation (NASDAQ: OMER), where he led clinical, safety, and medical functions for complement-targeted therapies.

Previously, Grauer held chief medical officer roles at Federation Bio and Corcept Therapeutics Incorporated. He spent over a decade at Amgen, Inc. in senior global development leadership positions, including Therapeutic Area Head for Bone, Nephrology, and Inflammation. His career began at Procter & Gamble Pharmaceuticals in medical affairs.

Grauer is an Associate Professor of Medicine at the University of Heidelberg Medical School in Germany, where he received his MD and completed clinical training in internal medicine and endocrinology. He has authored over 120 peer-reviewed publications in medical journals.

The company granted Grauer an inducement stock option valued at $1.34 million based on Black Scholes valuation. The options have a ten-year term and vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months thereafter.